Up a level |
Malaba, Thokozile R, Nakatudde, Irene, Kintu, Kenneth, Colbers, Angela, Chen, Tao ORCID: 0000-0002-5489-6450, Reynolds, Helen ORCID: 0000-0001-7443-4520, Read, Lucy, Read, Jim, Stemmet, Lee-Ann, Mrubata, Megan et al (show 18 more authors)
(2022)
72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.
LANCET HIV, 9 (8).
E534-E543.
Kintu, Kenneth, Malaba, Thokozile, Nakibuka, Jesca, Papamichael, Christiana, Colbers, Angela, Byrne, Kelly, Seden, Kay, Hodel, Eva Maria ORCID: 0000-0001-5821-1685, Chen, Tao ORCID: 0000-0002-5489-6450, Twimukye, Adelline et al (show 11 more authors)
(2020)
Dolutegravir versus efavirenz when starting HIV therapy in late pregnancy: a randomised controlled trial.
The Lancet HIV, 7 (5).
e332-e339.
Dickinson, Laura ORCID: 0000-0001-5557-9396, Walimbwa, Stephen, Singh, Yashna, Kaboggoza, Julian, Kintu, Kenneth, Sihlangu, Mary, Coombs, Julie-Anne, Malaba, Thokozile R, Byamugisha, Josaphat, Pertinez, Henry et al (show 11 more authors)
(2021)
Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1.
CLINICAL INFECTIOUS DISEASES, 73 (5).
E1200-E1207.
Waitt, Catriona ORCID: 0000-0003-0134-5855, Orrell, Catherine, Walimbwa, Stephen, Singh, Yashna, Kintu, Kenneth, Simmons, Bryony, Kaboggoza, Julian ORCID: 0000-0001-9510-0474, Sihlangu, Mary, Coombs, Julie-Anne, Malaba, Thoko et al (show 13 more authors)
(2019)
Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
PLOS MEDICINE, 16 (9).
e1002895-.
Ochanda, Perez Nicholas, Lamorde, Mohammed, Kintu, Kenneth, Wang, Duolao, Chen, Tao ORCID: 0000-0002-5489-6450, Malaba, Thokozile, Myer, Landon, Waitt, Catriona ORCID: 0000-0003-0134-5855, Reynolds, Helen ORCID: 0000-0001-7443-4520 and Khoo, Saye
(2022)
A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy.
AIDS RESEARCH AND THERAPY, 19 (1).
24-.